MMRGlobal Subsidiary Receives Clinical Trials Patent, as University of Texas Southwestern Medical Center & the University of Manchester Validate Patient Engagement in Clinical Trials - Seite 3

About MMRGlobal
MMRGlobal, Inc., through its wholly-owned subsidiary, MyMedicalRecords, Inc., provides secure and easy-to-use online Personal Health Records ("PHRs") and electronic safe deposit box storage solutions, serving consumers, healthcare professionals, employers, insurance companies, financial institutions, retail pharmacies, and professional organizations and affinity groups. The MyMedicalRecords PHR enables individuals and families to access their medical records and other important documents, such as birth certificates, insurance policies and wills, anytime from anywhere using the Internet. MyMedicalRecords is built on patented technologies to allow documents, images and voicemail messages to be transmitted and stored in the system using a variety of methods, including fax, phone, or file upload without relying on any specific electronic medical record platform to populate a user's account. MMR's professional offering, MMRPro, is designed to give physicians' offices an easy and cost-effective solution to digitizing paper-based medical records and sharing them with patients through an integrated patient portal. Through its merger with Favrille, Inc. in January 2009, MMR acquired intellectual property biotech assets that include anti-CD20 antibodies and data and samples from its FavId™ vaccine clinical trials for the treatment of B-Cell Non-Hodgkin's lymphoma. To learn more about MMRGlobal, visit www.mmrglobal.com. View demos and video tutorials of MMR's products and services at www.mmrtheater.com.

Forward-Looking Statements
All statements in this release that are not strictly historical in nature, including, without limitation, intellectual property licenses, intellectual property enforcement actions, infringement claims or litigation, and future performance, management's expectations, beliefs, intentions, estimates or projections, constitute "forward-looking statements." Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause MMR's actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. Some can be identified by the use of words (and their derivations) such as "expect," "plan," "possibility," "offer," "if," "negotiate," "when," "believe," "will," "estimate," and "continue," or the negative of these words. Such statements are necessarily based on assumptions and estimates and are subject to various risks and uncertainties, including those relating to the possible invalidity of the underlying assumptions and estimates and possible changes or developments in economic, social, political, business, industry, market, legal and regulatory circumstances and conditions and actions taken or omitted to be taken by third parties, including, but not limited to, customers, sources, suppliers, business partners, potential licensees, competitors and legislative, judicial and other governmental authorities and officials. Factors that could cause or contribute to such differences include, but are not limited to: unexpected outcomes with respect to intellectual property enforcement actions, claims of patent infringement and general IP litigation; our ability to develop, license and monetize our patent portfolio for both MMR's health IT and biotechnology IP assets in the U.S. and internationally; timing of milestone payments in connection with licensing our IP; and such other risks and uncertainties as detailed in MMR's public filings with the Securities and Exchange Commission. MMR is providing this information as of the date of this release and, except as required by law, does not undertake any obligation to update any forward-looking statements contained herein as a result of new information, future events or otherwise.